- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.
Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Kopran Limited has submitted their...
Kopran's Q1 FY26-27 revenue climbed 13.88% YoY to **153.99 Cr** (from 135.22 Cr). EBITDA also rose 11.13% YoY, hitting **15.88 Cr**. However, Net Profit dipped 10.19% YoY to **6.70 Cr**, with EPS at Rs. 1.39. The API segment was the largest contributor with **95.38 Cr** revenue, while Formulations generated **57.09...